Anbieter: BooksRun, Philadelphia, PA, USA
Hardcover. Zustand: Very Good. 2006. It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 223,21
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: PsychoBabel & Skoob Books, Didcot, Vereinigtes Königreich
EUR 232,03
Anzahl: 1 verfügbar
In den WarenkorbHardcover. Zustand: Very Good. Hardcover (no jacket; printed boards). Includes CD-ROM on inside rear board. Very good condition. Half-title page has partially separated from binding. Boards' leading corners are a little bumped and scuffed. Pages are clear. TA. Used.
Sprache: Englisch
Verlag: Springer New York, Springer New York, 2006
ISBN 10: 0387340564 ISBN 13: 9780387340562
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, 'drug-like' properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.
Sprache: Englisch
Verlag: Amer Assn of Pharmaceutical, 2006
ISBN 10: 0387340564 ISBN 13: 9780387340562
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 302,15
Anzahl: 2 verfügbar
In den WarenkorbHardcover. Zustand: Brand New. 1st hardback/cd-rom edition. 512 pages. 10.00x7.00x1.25 inches. In Stock.